Clinical Trials on Nonfunctional Pancreatic Neuroendocrine Tumor in Switzerland

Total 166 results

University Hospital, Geneva

Suspended

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Stage IB Skin Melanoma | Stages III Skin Melanoma | Stages II Skin Melanoma

Switzerland
Hoffmann-La Roche

Completed

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

Malignant Melanoma

Switzerland
Novartis Pharmaceuticals

Completed

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (CHIR-265-MEL01)

Metastatic Melanoma

Switzerland, United States
Incyte Corporation

Active, not recruiting

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Metastatic Merkel Cell Carcinoma

United Kingdom, United States, Germany, Canada, Czechia, Italy, France, Spain, Switzerland, Australia, Poland, Hungary
PharmaMar

Recruiting

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Glioblastoma | Pancreatic Adenocarcinoma | Neuroendocrine Tumors | Advanced Solid Tumors | Mesothelioma | SCLC | Gastric Carcinoma | Endometrial Carcinoma | Colorectal Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Epithelial Ovarian Carcinoma | Soft Tissue Sarcoma (Excluding GIST)

United States, Spain, France, Germany, Italy, Switzerland
Array BioPharma

Terminated

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Melanoma

Canada, Spain, Australia, Switzerland, Germany, United States
Institut Curie
Servier; UNICANCER

Completed

Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma (FOTEADJ)

Uveal Melanoma

France, Switzerland
University of Basel
Kantonsspital Aarau

Completed

Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions

Pheochromocytoma | Adrenal Tumor | Adrenal Mass | Adrenal Hyperplasia | Adrenal Metastases | Conn Adenoma

Switzerland
Pfizer

Completed

Use of 852A in Metastatic Cutaneous Melanoma.

Melanoma | Unresectable Metatstatic Cutaneous Melanoma

Switzerland, Germany, France
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Endometrial Carcinoma | Pancreatic Carcinoma

United States, Germany, Italy, Japan, Belgium, Switzerland, Korea, Republic of, Hong Kong, Finland, France, Spain
Celgene

Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Melanoma | Sarcoma, Soft Tissue | Cancer | Fibrosarcoma | Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Neoplasm | Malignant Melanoma | Tumors | Histiocytoma | Dermatofibrosarcoma | Sarcoma, Ewing's | Neoplasia | Ewing's Sarcoma | Ewing's Tumor | Sarcomas, Epitheliod | Sarcoma, Spindle Cell | Clinical Oncology | Oncology,... and other conditions

United States, Canada, Spain, France, United Kingdom, Italy, Switzerland
European Organisation for Research and Treatment...

Active, not recruiting

Minimal SN Tumor Burden (Minitub)

Cutaneous Melanoma

France, Italy, Switzerland, Belgium, Netherlands, Germany, Poland, Slovenia, United Kingdom, Spain
European Organisation for Research and Treatment...

Completed

E7070 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

France, Switzerland, Norway, Belgium, United Kingdom, Germany, Austria, Portugal, Italy
European Organisation for Research and Treatment...

Terminated

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Metastatic Cancer | Intraocular Melanoma

Switzerland, Italy, United Kingdom, Poland
Bristol-Myers Squibb

Completed

PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

Melanoma

Italy, Netherlands, Russian Federation, Czechia, Hungary, Ireland, Norway, Spain, Switzerland, Austria, Germany, Denmark, France, Belgium, United Kingdom, United States
University Hospital, Geneva

Recruiting

Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma

Ototoxicity | Vestibular Schwannoma

Switzerland
ITM Solucin GmbH
ABX CRO; PSI CRO

Active, not recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

Neuroendocrine Tumors

Germany, France, United States, United Kingdom, Australia, Italy, Belgium, Switzerland, Czechia, Spain, Austria, Netherlands, Poland, South Africa
Seagen Inc.

Recruiting

A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Colorectal Neoplasms | Pancreatic Neoplasms | Mesothelioma | Non-small Cell Lung Cancer | Cutaneous Melanoma

United States, Canada, Switzerland, France, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)

Melanoma

United States, Italy, United Kingdom, Netherlands, Canada, Germany, Australia, Spain, Switzerland, France
University of Zurich

Recruiting

Intrathecal Double Checkpoint Inhibition (IT-IO)

Melanoma Stage IV | Leptomeningeal Metastasis | Non-small Cell Lung Cancer Stage IV

Switzerland
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

France, Switzerland, Germany, Belgium, Netherlands, United Kingdom, Italy, Portugal, Austria
AstraZeneca

Completed

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Melanoma

Sweden, United States, Brazil, Czech Republic, France, Spain, United Kingdom, Germany, Norway, Hungary, Netherlands, Switzerland
AstraZeneca

Completed

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Melanoma

United States, Australia, Brazil, United Kingdom, Argentina, Austria, Canada, Denmark, France, Switzerland
Pfizer

Completed

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

BRAF or NRAS Mutant Metastatic Melanoma

United States, Netherlands, Italy, Germany, Switzerland
Delcath Systems Inc.
IQVIA Biotech

Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)

Melanoma, Ocular

United States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
Pfizer

Completed

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Melanoma and Metastatic Colorectal Cancer

United States, Spain, France, Japan, Australia, Switzerland, Norway
Philogen S.p.A.

Recruiting

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (NeoDREAM)

Melanoma Stage IIIB/C

Spain, United States, Switzerland
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
European Organisation for Research and Treatment...

Terminated

Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Metastatic Cancer | Melanoma (Skin)

France, Norway, Belgium, Netherlands, United Kingdom, Austria, Czech Republic, Germany, Italy, Portugal, Switzerland
Novartis Pharmaceuticals

Completed

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

Melanoma

United States, Belgium, Germany, Singapore, Italy, Australia, Netherlands, Sweden, Spain, Canada, Switzerland, Argentina, Brazil, China
sigma-tau i.f.r. S.p.A.

Completed

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

Malignant Melanoma

France, Germany, Hungary, Italy, Poland, Portugal, Spain, Switzerland
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)

Metastatic Melanoma

United States, Spain, Germany, United Kingdom, France, Hungary, Italy, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote-695)

Stage III/IV Melanoma

United States, Australia, Canada, Italy, Switzerland
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

Spain, United States, Australia, Austria, Poland, France, Germany, Italy, Switzerland
Bristol-Myers Squibb

Completed

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Melanoma

Australia, France, Italy, Poland, United Kingdom, United States, Spain, Belgium, Denmark, Germany, Norway, Switzerland, Argentina, Austria, Sweden, Czechia, Hungary, Netherlands, Mexico, Canada, Israel, South Africa
ImaginAb, Inc.

Recruiting

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT)

Melanoma | Renal Cell Carcinoma | Non Small Cell Lung Cancer | Merkel Cell Carcinoma, Unspecified

United States, Australia, Belgium, Netherlands, Switzerland, United Kingdom
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Melanoma (Skin)

Italy, France, Spain, Switzerland, United Kingdom, Belgium, Australia, Norway, Poland, Finland, Netherlands, Germany, Israel, Denmark, Serbia, Estonia, Portugal, Russian Federation
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Melanoma

Spain, United States, Australia, France, Israel, Italy, South Africa, Switzerland
Bristol-Myers Squibb

Completed

Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (CheckMate 401)

Melanoma

Australia, France, Italy, Belgium, Finland, Austria, Ireland, Sweden, Switzerland, United Kingdom, Germany, Norway
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)

Melanoma

France, Italy, Poland, United States, Brazil, Spain, Australia, Denmark, Germany, Austria, Netherlands, Russian Federation, Belgium, United Kingdom, Sweden, Switzerland
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Melanoma

France, Italy, Germany, Netherlands, Switzerland, United Kingdom, Austria, Australia
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Completed

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)

Metastatic Melanoma

Italy, Germany, Spain, Greece, Austria, France, Poland, Sweden, Switzerland, United Kingdom
European Organisation for Research and Treatment...

Unknown

Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Spain, United Kingdom, Belgium, Australia, Poland, Germany, Netherlands, Slovenia, Italy, Switzerland, Israel, Bulgaria, Croatia, Czech Republic, Estonia, Portugal, Turkey
Novartis Pharmaceuticals

Recruiting

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Metastatic Uveal Melanoma

United States, Australia, France, Netherlands, Switzerland, Germany, Spain
Bristol-Myers Squibb

Completed

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Melanoma

Germany, Italy, Sweden, United Kingdom, Belgium, Netherlands, Spain, Finland, Austria, Ireland, Poland, Portugal, Russian Federation, Switzerland, Czechia, Greece, Hungary, Luxembourg, Norway, Romania
GlaxoSmithKline

Completed

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Melanoma

United States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina

Clinical Trials on Nonfunctional Pancreatic Neuroendocrine Tumor in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations